ImmunoCellular Therapeutics, Ltd, a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, and Torrey Pines Institute for Molecular Studies in San Diego, California have identified several peptides which can generate CD-133 specific T-cells. CD-133 is found in high abundance on cancer stem cells (CSCs) which makes it promising for immunological targeting.

The parties have extended their research agreement to pursue additional studies to support an Investigational New Drug Application (IND) filing, as well as research on other cancer stem cell targets such as Numb and Notch proteins which are expressed on CSCs. Additional pre-clinical studies are underway to support the IND Filing.

"We are excited by the discoveries to date that could prove efficacious in treating cancer," said Manish Singh, president and chief executive officer of IMUC. "We look forward to expanding our relationship with the Torrey Pines Institute."

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers.

Torrey Pines Institute for Molecular Studies is a 501(c)(3) research center dedicated to conducting basic research to advance the understanding of human disease and the improvement of human health.